Protection against doxorubicin-induced alopecia in rats by liposome- entrapped monoclonal antibodies

A. L. Balsari, D. Morelli, S. Menard, U. Veronesi, M. I. Colnaghi

Research output: Contribution to journalArticlepeer-review


Alopecia is a common side effect of several anti-cancer drugs, including doxorubicin. Based on our recent observation that a monoclonal antibody (MAD11) directed against this anthracycline inhibits the systemic toxic effect of the drug in mice, we investigated the possibility that MAD11 administered topically might protect against doxorubicin-induced alopecia. In 31 of 45 young rats treated intraperitoneally with doxorubicin, alopecia was completely prevented by topical treatment of the skin with liposome- incorporated anti-doxorubicin monoclonal antibody. This type of treatment might find relevance in preventing anthracycline-induced alopecia in cancer patients. Our findings also provide the first demonstration that liposome- entrapped monoclonal antibodies are capable of penetrating the stratum corneum of the skin without losing their function.

Original languageEnglish
Pages (from-to)226-230
Number of pages5
JournalFASEB Journal
Issue number2
Publication statusPublished - 1994


  • alopecia
  • doxorubicin
  • liposomes
  • monoclonal antibodies

ASJC Scopus subject areas

  • Agricultural and Biological Sciences (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Cell Biology


Dive into the research topics of 'Protection against doxorubicin-induced alopecia in rats by liposome- entrapped monoclonal antibodies'. Together they form a unique fingerprint.

Cite this